Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) provided a corporate update on its barium and iodine contrast media projects, emphasizing progress toward bankable feasibility studies (BFS) and FDA regulatory submissions. The company aims to address critical supply chain vulnerabilities in the diagnostic imaging sector, where demand is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur’s strategy involves creating a secure, vertically integrated supply chain from mineral discovery to finished products.
The company is focused on completing two BFS: the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek (FC) barium contrast project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate, with an average grade of 98.8% BaSO4, exceeding Pharmaceutical Grade (97.5%). Recent testing confirmed purity levels, as detailed in a March 4, 2026 news release. Voyageur has completed product development for five Health Canada-approved barium products with Alberta Veterinary Laboratories, generating approximately C$32,000 in initial sales. These sales and pricing data are being incorporated into the FC barium BFS, expected in the second half of 2026, following geotechnical drilling at the FC quarry site.
FDA regulatory pathways for barium and iodine contrast media are expected to follow an 18 to 24-month review and approval process, potentially enabling U.S. barium market entry as soon as mid-2027 to late 2027. The company formally commenced the FDA approval process in February 2026 via the 505(b)(2) regulatory pathway, with first drafts of all barium FDA submission documents completed. The FDA is expected to provide all pending requirements in Q1 2026, after which a comprehensive submission will be executed. Voyageur plans to advance a generic iodine FDA license in the second half of 2026.
Voyageur is independently advancing a prefeasibility study for iodine contrast media drug production, integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. The project targets 35 million doses per year of iodine contrast drug production, leveraging iodine-rich brine from U.S. oil and gas operations. The Bayer Iodine project, supported by a US$2.35M funding arrangement, focuses on completing a BFS. Subject to successful completion, Bayer may provide capital financing for production, with Voyageur operating the project. All intellectual property will remain exclusively owned by Voyageur.
The company is engaging a global engineering company to complete the final two BFS, positioning Voyageur to establish a secure, large-scale North American supply of essential contrast media drugs. Upon completion, Voyageur will have finalized economics and plant design to vertically produce iodine and barium contrast media drugs, becoming the only vertically integrated radiology drug company. Management believes these efforts will position Voyageur as the only vertically integrated manufacturer of barium and iodine contrast media globally, reinforcing its value proposition: "From Earth to Bottle."
